A planning committee will be appointed by the National Academies of Sciences, Engineering, and Medicine to organize and convene a two-day, open workshop on pre-clinical diagnosis of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) for behavioral and social science researchers.
Topics may address:

• Can we afford the cost of a pre-clinical AD/ADRD diagnostic approach if/when it enters clinical practice?
• How will early disclosure impact other behavioral health services, family support, provider education and support, and clinical care?
• How, when, and what type of pre-clinical diagnostic information might be disclosed to stakeholders and what impact does this have on areas such as participant identity and self-concept; relationships with caregivers, providers, the healthcare system, and the broader society?
• What are other ethical implications of pre-clinical diagnosis in light of current knowledge from the use of AD/ADRD biomarkers and other relevant medical pre-clinical diagnostics (e.g., in cancer)?
• How can pre-clinical AD/ADRD diagnostics and early detection impact the design and conduct of AD/ADRD prevention trials?
• How can health equity issues in the use of pre-clinical AD/ADRD diagnostics and the conduct of AD/ADRD prevention trials be addressed?

A staff rapporteur will prepare a brief proceedings to summarize the discussion at the workshop which will be reviewed in accordance with institutional guidelines. Presentations and other background materials for the workshop will be made available on-line.